Structure and function of platelet receptors initiating blood clotting

Advances in Experimental Medicine and Biology

Volumn 844, Issue , 2014, Pages 263-275

  Gardiner, Elizabeth E ^a   Andrews, Robert K ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Coagulation; GPIb IX V; GPVI; Platelets

Indexed keywords

BACTERIAL PROTEIN; CD147 ANTIGEN; COLLAGEN; FC RECEPTOR; FC RECEPTOR IIA; FIBRIN; GLYCOCALICIN; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN VI; KININOGEN; LAMININ; LIGAND; MATRIX METALLOPROTEINASE; PLASMA KALLIKREIN; PROTHROMBIN; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE RECEPTOR; THROMBOSPONDIN; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 5; VON WILLEBRAND FACTOR; FIBRINOGEN RECEPTOR; GLYCOPROTEIN RECEPTOR GPIB-IX; PLATELET MEMBRANE GLYCOPROTEIN VI; PROTEIN BINDING; THROMBIN RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; BERNARD SOULIER DISEASE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; EXTRACELLULAR SPACE; GAIN OF FUNCTION MUTATION; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; MOLECULAR WEIGHT; NEUTROPHIL EXTRACELLULAR TRAP; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; VENOUS THROMBOEMBOLISM; ANIMAL; CHEMISTRY; PHYSIOLOGY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; HUMANS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84916215036     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2095-2_13     Document Type: Article

References (91)

1. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38:S26–34
2. del Conde I, Shrimpton CN, Thiagarajan P, López JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106(5):1604–11
3. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6):1143–56
4. Colace TV, Tormoen GW, McCarty OJ, Diamond SL. Microfluidics and coagulation biology. Ann Rev Biomed Eng. 2013;15:283–303
5. Jackson SP, Nesbitt WS, Westein E. Dynamics of platelet thrombus formation. J Thromb Haemost. 2009;7(s1):17–20
6. Winckers K, ten Cate H, Hackeng TM. The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis. Blood Rev. 2013;27(3):119–32
7. Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93(1):327–58
8. Chow TW, Hellums JD, Moake JL, Kroll MH. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood. 1992;80(1):113–20
9. Andrews RK, Shen Y, Gardiner EE, Berndt MC. Platelet adhesion receptors and (patho)physiological thrombus formation. Histol Histopathol. 2001;16(3):969–80
10. Cosemans JMEM, Schols SEM, Stefanini L, et al. Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood. 2011;117(2):651–60
11. van der Meijden PEJ, Schoenwaelder SM, Feijge MAH, et al. Dual P2Y12 receptor signaling in thrombin-stimulated platelets-involvement of phosphoinositide 3-kinase β but not γ isoform in Ca2+ mobilization and procoagulant activity. FEBS J. 2008;275(2):371–85
12. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood. 2011;118(26):6963–70
13. Gardiner EE, Karunakaran D, ShenY,Arthur JF,Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V byADAMfamily metalloproteinases. JThromb Haemost. 2007;5(7):1530–7
14. Al-Tamimi M, Grigoriadis G, Tran H, et al. Coagulation-induced shedding of platelet glycoprotein VI mediated by Factor Xa. Blood. 2011;117(14):3912–20
15. Rabie T, Strehl A, Ludwig A, Nieswandt B. Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem. 2005;280(15):14462–68
16. Andrews RK, Gardiner EE, Shen Y, Whisstock JC, Berndt MC. Glycoprotein Ib-IX-V. Int J Biochem Cell Biol. 2003;35(8):1170–4
17. Canobbio I, Balduini C, Torti M. Signalling through the platelet glycoprotein Ib-V-IX complex. Cell Signal. 2004;16(12):1329–44
18. López JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood. 1998;91(12):4397–418
19. Cranmer SL, Ashworth KJ, Yao Y, et al. High shear-dependent loss of membrane integrity and defective platelet adhesion following disruption of the GPIbα-filamin interaction. Blood. 2011;117(9):2718–27
20. Dicker IB, Pedicord DL, Seiffert DA, Jamieson GA, Greco NJ. Both the high affinity thrombin receptor (GPIb-IX-V) and GPIIb/IIIa are implicated in expression of thrombin-induced platelet procoagulant activity. Thromb Haemost. 2001;86(4):1065–9
21. Luo S-Z, Mo X, Afshar-Kharghan V, Srinivasan S, Lopez JA, Li R. Glycoprotein Ibα forms disulfide bonds with 2 glycoprotein Ibβ subunits in the resting platelet. Blood. 2007;109(2):603–9
22. Andrews RK, Berndt MC, López JA. The glycoprotein Ib-IX-V complex. In Michelson AD, editor. Platelets. San Diego: Academic; 2006:145–63
23. Ward CM, Andrews RK, Smith AI, Berndt MC. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet vonWillebrand factor receptor glycoprotein Ibα. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibα as a binding site for vonWillebrand factor and α-thrombin. Biochemistry. 1996;35(15):4929–38
24. Cauwenberghs N, Vanhoorelbeke K, Vauterin S, et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibα reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibα. Blood. 2001;98(3):652–60
25. Shen Y, Romo GM, Dong JF, et al. Requirement of leucine-rich repeats of glycoprotein (GP) Ibα for shear-dependent and static binding of vonWillebrand factor to the platelet membrane GP Ib-IX-V complex. Blood. 2000;95(3):903–10
26. Jurk K, Clemetson KJ, de Groot PG, et al. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J. 2003;17(11):1490–2
27. Li CQ, Vindigni A, Sadler JE, Wardell MR. Platelet glycoprotein Ibα binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin. J Biol Chem. 2001;276(9):6161–8
28. Huizinga EG, Tsuji S, Romijn RAP, et al. Structures of glycoprotein Ibα and its complex with vonWillebrand Factor A1 domain. Science. 2002;297(5584):1176–9
29. Dumas JJ, Kumar R, Seehra J, Somers WS, Mosyak L. Crystal structure of the GPIbα-thrombin complex essential for platelet aggregation. Science.2003;301(5630): 222–6
30. Bradford HN, Pixley RA, Colman RW. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem. 2000;275(30):22756–42
31. Yun TH, Baglia FA, Myles T, et al. Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ibα with thrombin anion-binding exosites I and II, respectively. J Biol Chem. 2003;278(48):48112–9
32. Joseph K, Nakazawa Y, Bahou WF, Ghebrehiwet B, Kaplan AP. Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Mol Med. 1999;5(8):555–63
33. Romo GM, Dong JF, Schade AJ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med. 1999;190(6):803–14
34. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein Ibα is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med. 2000;192(2):193–204
35. Arthur JF, Gardiner EE, Matzaris M, et al. Glycoprotein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets. Thromb Haemost. 2005;93(4):716–23
36. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. Mapping the glycoprotein Ibbinding site in the vonWillebrand factor A1 domain. J Biol Chem. 2000;275(25):19098–105
37. Shen Y, Dong Jf JF, Romo GM, et al. Functional analysis of the C-terminal flanking sequence of platelet glycoprotein Ibα using canine-human chimeras. Blood. 2002;99(1):145–50
38. Shen Y, Cranmer SL, Aprico A, et al. Leucine-rich repeats 2-4 (Leu60-Glu128) of platelet glycoprotein Ibα regulate shear-dependent cell adhesion to vonWillebrand factor. J Biol Chem. 2006;281(36):26419–26423
39. Dumas JJ, Kumar R, McDonagh T, et al. Crystal structure of the wild-type von Willebrand Factor A1-glycoprotein Iba complex reveals conformation differences with a complex bearing vonWillebrand Disease mutations. J Biol Chem. 2004;279(22):23327–34
40. McEwan PA, Andrews RK, Emsley J. Glycoprotein Ibα inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism. Blood. 2009;114(23):4883–5
41. Yago T, Lou J, Wu T, et al. Platelet glycoprotein Ibα forms catch bonds with human WT vWF but not with type 2B vonWillebrand disease vWF. J Clin Invest. 2008;118(9):3195–207
42. Bergmeier W, Piffath CL, Goerge T, et al. The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A. 2006;103(45):16900–5
43. Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibα and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost. 2008;99(2):264–70
44. Ravanat C, Strassel C, Hechler B, et al.A central role of GPIb-IX in the procoagulant function of platelets that is independent of the 45-kDa GPIbα N-terminal extracellular domain. Blood. 2010;116(7):1157–64
45. Boulaftali Y, Hess PR, Getz TM, et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest. 2013;123(2):908–16
46. Owens AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108(10):1284–97
47. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–34
48. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol. 2010;30(12):2362–7
49. Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Internal Med. 2013 24(5):393–400
50. Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264–74
51. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13(4):463–9
52. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271–81
53. Chavakis T, Santoso S, Clemetson KJ, et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem. 2003;278(46):45375–81
54. Liu J, Gao B-B, Clermont AC, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med. 2011;17(2):206–10
55. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood. 2012;119(25):5972–9
56. Shantsila E, Kamphuisen PW, Lip GYH. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. JThromb Haemost. 2010;8(11):2358–68
57. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles. Arterioscler Thromb Vasc Biol. 2006;26(12):2594–604
58. Ghosh A, Li W, Febbraio M, et al. Platelet CD36 mediates interactions with endothelial cellderived microparticles and contributes to thrombosis in mice. J Clin Invest. 2008;118(5): 1934–43
59. Pluskota E, Woody NM, Szpak D, et al. Expression, activation, and function of integrin αMβ2 (Mac-1) on neutrophil-derived microparticles. Blood. 2008;112(6):2327–35
60. De Haas CJC, Weeterings C, Vughs MM, De Groot PG, Van Strijp JA, Lisman T. Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibα and αIIbβ3. J Thromb Haemost. 2009;7(11):1867–74
61. Hu H, Armstrong PCJ, Khalil E, et al. GPVI and GPIbα mediate Staphylococcal Superantigenlike protein 5 (SSL5) induced platelet activation and direct toward glycans as potential inhibitors. PLoS ONE. 2011;6(4):e19190
62. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5
63. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10(1):136–44
64. Ward CM, Tetaz TJ, Andrews RK, Berndt MC. Binding of the vonWillebrand factorA1 domain to histone. Thromb Res. 1997;86(6):469–77
65. Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor γ chain complex on human platelets. J Exp Med. 1998;188(2):267–76
66. Jandrot-Perrus M, Busfield S, Lagrue A-H, et al. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood. 2000;96(5):1798–807
67. Suzuki-Inoue K, Tulasne D, Shen Y, et al. Association of Fyn and Lyn with the prolinerich domain of glycoprotein VI regulates intracellular signaling. J Biol Chem. 2002;277(24): 21561–6
68. Ruan CG, Du XP, Xi XD, Castaldi PA, Berndt MC.Amurine antiglycoprotein Ib complex monoclonal antibody, SZ2, inhibits platelet aggregation induced by both ristocetin and collagen. Blood. 1987;69(2):570–7
69. Ohlmann P, Hechler B, Ravanat C, et al. Ex vivo inhibition of thrombus formation by an antiglycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. J Thromb Haemost. 2008;6(6):1003–11
70. Schulte V, Reusch HP, Pozgajova M, Varga-Szabo D, Gachet C, Nieswandt B. Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. Arterioscler Thromb Vasc Biol. 2006; 26 (7): 1640–1647
71. Gilio K, van Kruchten R, Braun A, et al. Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation. J Biol Chem. 2010;285(31):23629–38
72. Heemskerk JW, Siljander P, Vuist WM, et al. Function of glycoprotein VI and integrin α2β1 in the procoagulant response of single, collagen-adherent platelets. Thromb Haemost. 1999;81(5):782–92
73. Siljander P, Farndale RW, Feijge MAH, et al. Platelet adhesion enhances the glycoprotein VIdependent procoagulant response: Involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol. 2001;21(4):618–27
74. Seizer P, Borst O, Langer HF, et al. EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction. Thromb Haemost. 2009;101(4):682–6
75. Schulz C, von Bruhl ML, Barocke V, et al. EMMPRIN (CD147/basigin) mediates plateletmonocyte interactions in vivo and augments monocyte recruitment to the vascular wall. J Thromb Haemost. 2011;9(5):1007–19
76. Coller BS, Kalomiris E, Steinberg M, Scudder LE. Evidence that glycocalicin circulates in normal plasma. J Clin Invest. 1984;73(3):794–9
77. Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoproteinVI by a platelet-derived metalloproteinase. Blood. 2004;104(12):3611–7
78. Al-Tamimi M, Arthur JF, Gardiner EE, Andrews RK. Focusing on plasma glycoprotein VI. Thromb Haemost. 2012;107(4):648–55
79. Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets. 2009;20(3):143–9
80. Al-Tamimi M, Gardiner EE, Thom JY, et al. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke. 2011;42(2):498–500
81. Bigalke B, Potz O, Kremmer E, et al. Sandwich immunoassay for soluble glycoprotein VI in patients with symptomatic coronary artery disease. Clin Chem. 2011;57(6):898–904
82. Al-Tamimi M, Tan C, Qiao J, et al. Pathological shear triggers shedding of vascular receptors: a novel mechanism for downregulation of platelet glycoprotein (GP)VI in stenosed coronary vessels. Blood. 2012;119(18):4311–20
83. Gardiner EE, Karunakaran D, Arthur JF, et al. Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: De-ITAM-izing FcγRIIa. Blood. 2008;111(1):165–74
84. Gardiner EE, Al-Tamimi M, Mu FT, et al. Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost. 2008;6(7):1175–82
85. Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcγRIIA. Blood. 2001;98(8):2442–7
86. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84(11):3691–9
87. Tardy-Poncet B, Piot M, Chapelle C, et al. Thrombin generation and heparin-induced thrombocytopenia. J Thromb Haemostas. 2009;7(9):1474–81
88. Andrews RK, Du X, Berndt MC. The 14-3-3ζ-GPIb-IX-V complex as an antiplatelet target. Drug News Perspect. 2007;20(5):285–92
89. Clemetson KJ, Clemetson JM. Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb Haemost. 2008;99(3):473–9
90. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med. 2011;17(11):1423–36
91. Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP. New insights into the haemostatic function of platelets. Br J Haematol. 2009;147(4):415–30.